New Treatment Approved for NSCLC with High Level of c-Met Protein
On May 14, 2025, the US Food and Drug Administration (FDA) announced the approval of telisotuzumab vedotin-tllv (EMRELIS™) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with high levels of c-Met protein who have been previously treated with a systemic therapy, such as immunotherapy or chemotherapy.
This ADC, or antibody-drug conjugate, is the first approval of its kind. This ADC treatment is designed with two key elements.